The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Gastric Inhibitory Polypeptide as an Endogenous Factor Promoting New Bone Formation after Food Ingestion
Open accessAbstract
Calcium plays a fundamental role as second messenger in intracellular signaling and bone serves as the body’s calcium reserve to tightly maintain blood calcium levels. Calcium in ingested meal is the main supply and inadequate calcium intake causes osteoporosis and bone fracture. Here, we describe a novel mechanism of how ingested calcium is deposited on bone. Meal ingestion elicits secretion of the gut hormone gastric inhibitory polypeptide (GIP) from endocrine K cells in the duodenum. Bone histomorphometrical analyses revealed that bone formation parameters in the mice lacking GIP receptor (GIPR−/−) were significantly lower than those of wild-type (GIPR+/+) mice, and that the number of osteoclasts, especially multinuclear osteoclasts, was significantly increased in GIPR−/− mice, indicating that GIPR−/− mice have high-turnover osteoporosis. In vitro examination showed the percentage of osteoblastic cells undergoing apoptosis to be significantly decreased in the presence of GIP. Because GIPR−/− mice exhibited an increased plasma calcium concentration after meal ingestion, GIP directly links calcium contained in meal to calcium deposition on bone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“GIP also stimulates bone formation by inhibiting osteoclast apoptosis [52].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [52]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These findings suggest that liraglutide specifically reduces bone resorption without influencing bone formation.368”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [368]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,344
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,345
Self-citationDawson‐Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371003 · Cited by 2,276
Lips, P. (2001) · Endocrine reviews · doi:10.1210/edrv.22.4.0437 · Cited by 2,203
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,720
The Osteoblast: A Sophisticated Fibroblast under Central Surveillance
Ducy, P. F., Schinke, T., & Karsenty, G. (2000) · Science · doi:10.1126/science.289.5484.1501 · Cited by 1,137
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P. K., PARFITT, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,042
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Self-citationA Controlled Trial of the Effect of Calcium Supplementation on Bone Density in Postmenopausal Women
Dawson‐Hughes, B., Dallal, G. E., Krall, E. A., Sadowski, L., Sahyoun, N. R., & Tannenbaum, S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009273231305 · Cited by 945
Cited by
Sorted by citations
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“368 Since GLP-1R is expressed in thyroid C cells and GLP-1 directly stimulates the secretion of calcitonin, which is a potent inhibitor of bone resorption in osteoclasts, GLP-1 may contribute to the nutrient-mediated reduction in bone resorption.”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Self-citationThe Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
Self-citationExtrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Self-citationSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 255
Self-citationThe Impact of Diabetes and Diabetes Medications on Bone Health
Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 211
Effects of glucose-dependent insulinotropic peptide on osteoclast function
Zhong, Q., Itokawa, T., Sridhar, S., Ding, K., Xie, D., Kang, B., Bollag, W. B., Bollag, R. J., Hamrick, M. W., Insogna, K. L., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00364.2006 · Cited by 206
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
Receptors and effects of gut hormones in three osteoblastic cell lines
Pacheco-Pantoja, E. L., Ranganath, L. R., Gallagher, J. A., Wilson, P. J., & Fraser, W. D. (2011) · BMC Physiology · doi:10.1186/1472-6793-11-12 · Cited by 175
Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 173
Nasteska, D., Harada, N., Suzuki, K., Yamane, S., Hamasaki, A., Joo, E., Iwasaki, K., Shibue, K., Harada, T., & Inagaki, N. (2014) · Diabetes · doi:10.2337/db13-1563 · Cited by 171
Self-citationLin, P., Niimi, H., Ohsugi, Y., Tsuchiya, Y., Shimohira, T., Komatsu, K., Liu, A., Shiba, T., Aoki, A., Iwata, T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168900 · Cited by 164
GPR119 agonists for the treatment of type 2 diabetes
Jones, R. M., Leonard, J. N., Buzard, D. J., & Lehmann, J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903153878 · Cited by 155
Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass
Xie, D., Zhong, Q., Ding, K.-H., Cheng, H., Williams, S., Correa, D., Bollag, W. B., Bollag, R. J., Insogna, K., Troiano, N., et al. (2007) · Bone · doi:10.1016/j.bone.2007.01.007 · Cited by 144
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 144
Kim, J.-Y., Lee, S.-K., Jo, K.-J., Song, D.-Y., Lim, D.-M., Park, K.-Y., Bonewald, L. F., & Kim, B.-J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.001 · Cited by 137
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
Nissen, A., Christensen, M., Knop, F., Vilsbøll, T., Holst, J., & Hartmann, B. (2014) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2014-2547 · Cited by 122
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 122
Pathophysiology of Bone Fragility in Patients with Diabetes
Palermo, A., D'Onofrio, L., Buzzetti, R., Manfrini, S., & Napoli, N. (2017) · Calcified Tissue International · doi:10.1007/s00223-016-0226-3 · Cited by 94
Godinho, R., Mega, C., Teixeira‐Lemos, E., Carvalho, E., Teixeira, F. J., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 111
Torekov, S. S., Harsløf, T., Rejnmark, L., Eiken, P., Jensen, J. B., Herman, A. P., Hansen, T. F., Pedersen, O. B., Holst, J. J., & Langdahl, B. L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3766 · Cited by 109
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D’Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 107
Schiellerup, S. P., Skov‐Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00075 · Cited by 110
Therapeutic potential for GIP receptor agonists and antagonists
Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 105
Christensen, M., Lund, A., Calanna, S., Jørgensen, N. R., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01949 · Cited by 101
Diabetes pharmacotherapy and effects on the musculoskeletal system
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I. R., & Thrailkill, K. M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 103
Suzuki, K., Harada, N., Yamane, S., Nakamura, Y., Sasaki, K., Nasteska, D., Joo, E., Shibue, K., Harada, T., Hamasaki, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.423137 · Cited by 105
Self-citationThe role of GPCRs in bone diseases and dysfunctions
Luo, J., Sun, P., Siwko, S. K., Liu, M., & Xiao, J. (2019) · Bone Research · doi:10.1038/s41413-019-0059-6 · Cited by 102
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 103
Rao, R. S., & Kini, S. U. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0305-x · Cited by 93
Diet: Friend or Foe of Enteroendocrine Cells: How It Interacts with Enteroendocrine Cells
Morán‐Ramos, S., Tovar, A. R., & Torres, N. (2012) · Advances in Nutrition · doi:10.3945/an.111.000976 · Cited by 95
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Self-citationBone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass
Hage, M. P., & Fuleihan, G. E. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2480-9 · Cited by 93
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Yamaoka‐Tojo, M., Tojo, T., Takahira, N., Matsunaga, A., Aoyama, N., Masuda, T., & Izumi, T. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-17 · Cited by 86
Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus
Mansur, S. A., Mieczkowska, A., Bouvard, B., Flatt, P. R., Chappard, D., Irwin, N., & Mabilleau, G. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25033 · Cited by 82
Antidiabetic therapy effects on bone metabolism and fracture risk
Montagnani, A., & Gonnelli, S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12077 · Cited by 79
Gaudin-Audrain, C., Irwin, N., Mansur, S. A., Flatt, P. R., Thorens, B., Baslé, M. F., Chappard, D., & Mabilleau, G. (2012) · Bone · doi:10.1016/j.bone.2012.11.039 · Cited by 80
Impact of Glucose-Dependent Insulinotropic Peptide on Age-Induced Bone Loss
Ding, K.-H., Shi, X., Zhong, Q., Kang, B., Xie, D., Bollag, W. B., Bollag, R. J., Hill, W., Washington, W., Mi, Q., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071202 · Cited by 79
A novel GIP receptor splice variant influences GIP sensitivity of pancreatic β-cells in obese mice
Harada, N., Yamada, Y., Tsukiyama, K., Yamada, C., Nakamura, Y., Mukai, E., Hamasaki, A., Liu, X., Toyoda, K., Seino, Y., et al. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00358.2007 · Cited by 79
Self-citationGilbert, M. P., Marre, M., Holst, J. J., Garber, A. J., Baeres, F. M. M., Thomsen, H. F., & Pratley, R. E. (2015) · Endocrine Practice · doi:10.4158/ep15758.or · Cited by 78
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Kyle, K., Willett, T., Baggio, L., Drucker, D., & Grynpas, M. (2011) · Endocrinology · doi:10.1210/en.2010-1098 · Cited by 78
Casimiro, I., Sam, S., & Brady, M. (2019) · Physiological Reports · doi:10.14814/phy2.14111 · Cited by 72
Luo, G., Liu, H., & Lu, H. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12777 · Cited by 70
Stemmer, K., Bielohuby, M., Grayson, B. E., Begg, D. P., Chambers, A. P., Neff, C., Woods, S. C., Erben, R. G., Tschöp, M. H., Bidlingmaier, M., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2130 · Cited by 66
Walsh, J., & Henriksen, D. B. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.020 · Cited by 66
GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells
Hansen, M. S., Søe, K., Christensen, L. L., Fernandez-Guerra, P., Hansen, N. W., Wyatt, R. A., Martin, C., Hardy, R. S., Andersen, T. L., Olesen, J. B., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac004 · Cited by 62
The role of endogenous GIP and GLP-1 in postprandial bone homeostasis
Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., ROSENKILDE, M. M., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115553 · Cited by 63
Speakman, J. R. (2013) · Human Heredity · doi:10.1159/000353585 · Cited by 61
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Diabetes Mellitus-induced Bone Fragility
Kanazawa, I., & Sugimoto, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0905-18 · Cited by 64
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
The entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 58
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 60
Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide
Yamada, Y., Miyawaki, K., Tsukiyama, K., Harada, N., Yamada, C., & Seino, Y. (2006) · Diabetes · doi:10.2337/db06-s011 · Cited by 55
Self-citationHolst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 72
Incretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 54
Self-citationIrwin, N., Gault, V. A., & Flatt, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.513381 · Cited by 55
Kizilkaya, H. S., Sørensen, K. V., Kibsgaard, C. J., Gasbjerg, L. S., Hauser, A. S., Sparre-Ulrich, A. H., Grarup, N., & Rosenkilde, M. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.749607 · Cited by 52
AOYAMA, E., Watari, I., Podyma‐Inoue, K. A., Yanagishita, M., & Ono, T. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1787 · Cited by 53
Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
Kubota (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1061w · Cited by 52
Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone
Naot, D., & Cornish, J. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00070 · Cited by 56
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Knop, F. K., Hansen, K. B., & Knop, F. K. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7004 · Cited by 52
Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives
Mesa, F., Magán‐Fernández, A., Castellino, G., Chianetta, R., Nibali, L., & Rizzo, M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.001 · Cited by 51
Mabilleau, G., Perrot, R., Mieczkowska, A., Boni, S., Flatt, P. R., Irwin, N., & Chappard, D. (2016) · Bone · doi:10.1016/j.bone.2016.07.014 · Cited by 49
Westberg-Rasmussen, S., Starup‐Linde, J., Hermansen, K., Holst, J. J., Hartmann, B., Vestergaard, P., & Gregersen, S. (2017) · Bone · doi:10.1016/j.bone.2017.01.027 · Cited by 50
Mieczkowska, A., Mansur, S., Bouvard, B., Flatt, P. R., Thorens, B., Irwin, N., Chappard, D., & Mabilleau, G. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2845-8 · Cited by 47
GIP and the gut-bone axis – Physiological, pathophysiological and potential therapeutic implications
Stensen, S., Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Christensen, M., & Knop, F. K. (2019) · Peptides · doi:10.1016/j.peptides.2019.170197 · Cited by 49
Gabe, M. B. N., Skov‐Jeppesen, K., Gasbjerg, L. S., Schiellerup, S. P., Martinussen, C., Gadgaard, S., Boer, G. A., Oeke, J., Torz, L., Veedfald, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106058 · Cited by 47
Diabetes Drug Effects on the Skeleton
Chandran, M. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0203-x · Cited by 47
Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition
Epstein, S., Defeudis, G., Manfrini, S., Napoli, N., & Pozzilli, P. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3454-x · Cited by 46
Ussar, S., Haering, M.-F., Fujisaka, S., Lutter, D., Lee, K. Y., Li, N., Gerber, G. K., Bry, L., & Kahn, C. R. (2017) · Diabetes · doi:10.2337/db15-1349 · Cited by 47
Challenges to Improve Bone Healing Under Diabetic Conditions
Chen, Y., Zhou, Y., Lin, J., & Zhang, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.861878 · Cited by 48
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 44
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“GIP also stimulates bone formation by inhibiting osteoclast apoptosis [52].”
BackgroundYamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Yamane, S., Harada, N., Miyawaki, K., Seino, Y., & Inagaki, N. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.128 · Cited by 42
Self-citationMaino, B., Ciotti, M. T., Calissano, P., & Cavallaro, S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045596 · Cited by 41
Pros and cons of fatty acids in bone biology
Wauquier, F., Léotoing, L., Philippe, C., Spilmont, M., Coxam, V., & Wittrant, Y. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.03.001 · Cited by 41
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 44
Yamamoto, M. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0129 · Cited by 38
The Effects of Bariatric Surgery on Bone Metabolism
Gregory, N. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.011 · Cited by 38
Mansur, S. A., Mieczkowska, A., Flatt, P. R., Bouvard, B., Chappard, D., Irwin, N., & Mabilleau, G. (2016) · Bone · doi:10.1016/j.bone.2016.04.001 · Cited by 37
Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
Kitaura, H., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., Kanou, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126578 · Cited by 42
Nirwan, N., & Vohora, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.944323 · Cited by 40
Searching for the physiological role of glucose‐dependent insulinotropic polypeptide
Holst, J. J., Windeløv, J. A., Boer, G. A., Pedersen, J., Svendsen, B., Christensen, M., Torekov, S., Asmar, M., Hartmann, B., & Nissen, A. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12488 · Cited by 36
Glorie, L., D’Haese, P. C., & Verhulst, A. (2016) · Bone · doi:10.1016/j.bone.2016.08.009 · Cited by 37
Hansen, M. S., Tencerová, M., Frølich, J. S., Kassem, M. S., & Frost, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12850 · Cited by 37
Review article: effects of type 2 diabetes therapies on bone metabolism
Vianna, A. G. D., Sanches, C. P., & Barreto, F. C. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0274-5 · Cited by 36
Structure and Function of Bone Marrow Adipocytes
de Paula, F. J. A., & Rosen, C. J. (2017) · Comprehensive physiology · doi:10.1002/cphy.c170010 · Cited by 39
Wu, X., Li, S., Xue, P., & Li, Y. (2018) · PubMed Central · doi:10.14348/molcells.2018.2340 · Cited by 34
Skeleton and Glucose Metabolism: A Bone-Pancreas Loop
Faienza, M. F., Luce, V., Ventura, A., Colaianni, G., Colucci, S. C., Cavallo, L., Grano, M., & Brunetti, G. (2015) · International Journal of Endocrinology · doi:10.1155/2015/758148 · Cited by 35
Gastrointestinal peptides and bone health
Wong, I. P. L., Baldock, P. A. J., & Herzog, H. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283344a05 · Cited by 35
Biomarkers of Osteoporosis: An Update
Parveen, B., Parveen, A., & Vohora, D. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190204165207 · Cited by 33
Baldassano, S., Gasbjerg, L. S., Kizilkaya, H. S., ROSENKILDE, M. M., Holst, J. J., & Hartmann, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00492 · Cited by 33
Recent advances of GIP and future horizons
Holst, J. J., & ROSENKILDE, M. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
Qiu, Y., Fu, B., Luo, D., Wang, H., Cao, H., Chen, X., Tian, L., & Yu, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.856954 · Cited by 32
Metadata
- Authors
- Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., Udagawa, N., Takahashi, N., Tanaka, K., Oiso, Y., & Seino, Y.
- Affiliations
- Nagoya University (JP)
- Departments of Diabetes and Clinical Nutrition (K.Ts., Y.Y., C.Y., N.H., Y.K., M.O., Y.S.), Kyoto 606-8507, Japan;
- Kyoto University (JP)
- Niigata University (JP)
- Department of Biochemistry (M.S., N.U.), Nagano 399-0781, Japan;
- Matsumoto Dental University (JP)
- Kyoto Women's University (JP)
- Kansai Electric Power Hospital (JP)
- Corresponding author
- Yamada, Yuichiro
- ORCID
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2006-07-01
- Volume
- 20
- Issue
- 7
- Pages
- 1644-1651
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2103318165
- Cited by
- 198
- References
- 33
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 6 · 2020: 8 · 2019: 17 · 2018: 15 · 2017: 11 · 2016: 12 · 2015: 15 · 2014: 12 · 2013: 18 · 2012: 6
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, bone formation, calcium homeostasis, meal ingestion, gastrointestinal hormones, K cells, osteoclasts, osteoblast apoptosis, plasma calcium, bone histomorphometry
- MeSH terms
- Animals, Bone Resorption, Calcium, Eating, Gastric Inhibitory Polypeptide, Male, Mice, Transgenic, Models, Biological, Osteoblasts, Osteoclasts, Osteogenesis, Osteoporosis, Tibia, Signal Transduction, Apoptosis Regulatory Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
